Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Preleukemia in long-term plasmacytoma-regressor mice

O Sagi-Assif1, L Trakhtenbrot, D Douer

  • 1Department of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel.

International Journal of Cancer
|June 4, 1998
PubMed
Summary

Chemotherapy survivors may harbor preleukemic cells. Adoptive transfer of these cells from plasmacytoma-regressor mice (PRM) induced leukemia in recipients, suggesting a model for chemotherapy-related leukemia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trials.

Bone marrow transplantation·2024
Same author

Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trials.

Bone marrow transplantation·2024
Same author

The MLL recombinome of acute leukemias in 2017.

Leukemia·2017
Same author

Invasive Aspergillosis in Neutropenic Patients with Hematological Disorders.

Leukemia & lymphoma·2016
Same author

Autologous transplant remains the preferred therapy for relapsed APL in CR2.

Bone marrow transplantation·2016
Same author

Very late relapse of AML after allogeneic hematopoietic cell transplantation is often extramedullary.

Bone marrow transplantation·2016

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • Melphalan chemotherapy for plasmacytoma can cause persistent immunohematological abnormalities in mice.
  • These abnormalities include immunosuppression, myeloproliferation, and altered growth factor responses.
  • Mice without plasmacytoma treated with melphalan do not develop these issues.

Purpose of the Study:

  • To investigate the potential for preleukemic cells in mice that survived plasmacytoma chemotherapy.
  • To determine if these preleukemic cells can induce leukemia in recipient mice.

Main Methods:

  • Adoptive transfer of splenocytes from plasmacytoma-regressor mice (PRM) to irradiated syngeneic recipients.
  • Monitoring recipients for leukemia development via blood counts and spleen histology.

Related Experiment Videos

  • Secondary adoptive transfer of cells from primary recipients to non-irradiated secondary recipients.
  • Sex chromosome analysis to confirm cell origin.
  • Characterization of leukemic cells for surface markers.

    • Main Results:

    • Plasmacytoma-regressor mice harbor preleukemic cells that do not progress to leukemia in the host.
    • Adoptive transfer of splenocytes from PRM induced overt leukemia in irradiated recipients.
    • Leukemia developed in 100% of secondary recipients after transfer from primary recipients.
    • Sex chromosome analysis confirmed leukemic cells originated from PRM donors.
    • Established leukemic lines expressed hematopoietic progenitor and T cell markers.

    Conclusions:

    • Plasmacytoma-regressor mice contain transplantable preleukemic cells.
    • These cells can induce leukemia in recipient mice, indicating a potential mechanism for chemotherapy-related leukemia.
    • PRM serve as a valuable animal model for studying the development of chemotherapy-induced leukemia.